Table 3.

Predictors of seroconversion of the infants to LR-HPV (HPV 6, 11) and HR-HPV (HPV 16, 18, 45) L1 antigens during the follow-up in time-dependent GEE modelling¹ run in univariate model and as adjusted for other covariates.

Covariates	Seroconversion to LR-HPV (HPV6 L1 and/or HPV 11L1)*						Seroconversion to HR-HPV (HPV 16L1, HPV 18L1 and/or HPV 45L1)
	Crude OR	95%CI	Significance	**Adjusted OR	95%CI	Significance	Crude OR	95%CI	Significance	@Adjusted OR	95%CI	Significance
Age (categorical) of mother	1.2	0.54–2.70	0.650	0.2	0.02–2.36	0.196	2.6	0.91–7.42	0.074	1.6	0.27–9.61	0.609
Genital HR-HPV DNA status of mother2	0.7	0.46–1.09	0.121	1.0	0.98–1.00	0.082	1.2	0.74–2.07	0.421	1.2	0.54–2.58	0.686
Oral HR-HPV DNA status of mother2	1.1	0.84–1.55	0.413	1.0	1.00–1.00	0.996	1.2	0.82–1.69	0.371	1.1	0.66–1.98	0.640
Baseline Pap cytology of mother (ASCUS cut-off)	0.9	0.60–1.41	0.693	1.0	0.99–1.00	0.428	1.3	0.81–2.22	0.249	1.5	0.62–3.59	0.366
Seroconversion to LR-HPV of mother (no conversion; ref)	1.9	1.14–3.13	0.014	1.8	0.60–5.24	0.301	1.7	0.96–3.00	0.066	1.3	0.53–2.94	0.607
Smoking status of mother	1.1	0.79–1.40	0.741	0.9	0.36–2.31	0.842	1.2	0.68–1.99	0.585	1.1	0.51–2.47	0.769
Mother’s history of genital warts (no history; ref)	1.2	0.72–2.12	0.438	0.5	0.17–1.42	0.188	0.7	0.40–1.27	0.245	0.5	0.20–1.08	0.074
Mother’s history of oral warts (no history; ref)	7.5	0.88–63.23	0.065	55.9	6.74–463.08	0.0001	1.1	0.20–5.66	0.943	1.3	0.14–11.75	0.818
Mother’s history of skin warts (no history; ref)	1.2	0.89–1.54	0.253	1.3	0.89–2.05	0.162	0.8	0.57–1.09	0.154	0.9	0.60–1.29	0.500
Sex of infant	1.0	0.62–1.54	0.910	0.7	0.27–1.67	0.389	1.1	0.63–1.78	0.816	1.0	0.47–2.27	0.927
Mode of delivery	1.0	0.57–1.85	0.927	2.4	0.73–7.91	0.148	0.7	0.32–1.41	0.324	0.6	0.20–1.59	0.280
Genital HR-HPV DNA status of infant2	0.8	0.61–1.05	0.112	1.0	0.99–1.00	0.482	0.9	0.66–1.19	0.418	0.9	0.53–1.54	0.706
Oral HR-HPV DNA status of infant2	1.0	0.75–1.27	0.844	1.0	1.00–1.01	0.140	0.9	0.71–1.23	0.644	0.8	0.46–1.57	0.602
Atopia	1.1	0.57–2.14	0.769	0.9	0.63–1.33	0.630	0.6	0.30–1.24	0.172	NCF	NCF	NCF
Allergy	1.0	0.77–1.29	0.985	1.4	0.53–3.73	0.500	0.7	0.46–1.12	0.149	NCF	NCF	NCF
Oral warts at 36 months	NC	NC	NC	NC	NC	NC	NC	NC	NC	NCF	NCF	NCF
Genital warts at 36 months	NC	NC	NC	NC	NC	NC	NC	NC	NC	NCF	NCF	NCF
Hand warts at 36 months	5.4	0.61–47.33	0.128	42.8	4.15–440.76	0.002	2.6	0.51–13.50	0.247	NCF	NCF	NCF

Statistically significant values are marked as bolded.

*Binary outcome (Conversion/No conversion) detected during the 36-mo follow-up (Cut-off 200 MFI, and > 2 × increase of Ab titers in two subsequent samples); ¹Results obtained from time-dependent GEE with logit link for binary outcomes clustered by child ID number; **adjusted for all other covariates in the model; ²High-Risk (HR)-HPV detected at any follow-up (FU) visit;

OR, odds ratio; CI, confidence interval; NC, not computable, no relevant cases; NCF, not computable due to failure to achieve convergence.